Comparison of E. coli and Insect Baculovirus Expression Systems

Principle of Escherichia coli Expression System

The Escherichia coli expression system is an expression system that efficiently expresses genes encoding protective antigens of pathogenic microorganisms in Escherichia coli through DNA recombination technology. It is currently the most commonly used system for recombinant protein expression. The E. coli expression system has been studied earlier and has many advantages such as clear background, simple operation, and high expression. The expression level is significantly higher than that of mammalian expression systems, but it also has corresponding shortcomings. For example, the E. coli system cannot secrete the expressed protein outside the cell, the ability to form disulfide bonds is limited, and complex modifications of protein expression (such as Glycosylation, etc.).

Principle of Baculovirus Expression System

Insect baculovirus expression vector system is a recombinant protein production system that uses recombinant insect baculovirus carrying foreign target genes as a vector for expression and production in insects or insect cultured cells.

Since the cycle required by this system is much shorter than that of animal or plant systems, individual insects or their cultured cells can be used for large-scale expression production, and the production of recombinant protein is high. The post-translational processing of protein is better than that of bacterial and yeast production systems. Because the insect baculovirus has a restricted host range, it only infects insects of specific species and their cells, and has no ability to infect humans and animals and other vertebrates. Therefore, it is safer than mammals and their cultured cell production systems. Advantages and become one of the most effective eukaryotic expression systems.

E. coli and Insect Baculovirus Expression Systems

Advantages and Disadvantages of Each Expression System

Escherichia coli expression system

Advantages	Disadvantages	Technical difficulties
The operation is simple, the cycle is short, the income is large, and the expression product is stable.	Easy to form inclusion bodies; The protein lacks post-translational modification;	How to realize the expression of a large number of soluble proteins; How to realize glycosylation modification of protein.

Baculovirus Expression System

Advantages	Disadvantages	Technical difficulties
Carry out post-translational glycosylation modification of the protein.	High cost, low protein expression, difficult to form seed batches	Increase protein expression and reduce production costs. Improve inter-batch stability.

Medicilon’s Baculovirus-insect Cell Expression Services Platform

Medicilon researchers establish a well-developed baculovirus-insect cell expression services platform. We provide the expression and purification services on preparation of recombinant baculovirus and recombinant protein. We have a good track record in producing kinase and recombinant protein complexes.

Service：

Generation of recombinant Bacmid DNA

Preparation of recombinant baculovirus

Titration of baculovirus

Protein expression verification and optimization

Small scale expression and purification of recombinant protein in insect cell

Scale up expression and purification of recombinant protein in insect cell

Baculovirus Expression Vector System

Baculovirus Expression System

Introduction of Bac-to-Bac System

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客